These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8575496)

  • 1. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2.
    Tubaro A; Stoppacciaro A; Velotti F; Bossola PC; Cusumano G; Vicentini C; De Carli P; Ruco L; Santoni A; Cancrini A
    Eur Urol; 1995; 28(4):297-303. PubMed ID: 8575496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study.
    Gomella LG; McGinnis DE; Lattime EC; Butler K; Baltish M; Thompson I; Marshall ME
    Cancer Biother; 1993; 8(3):223-7. PubMed ID: 7804362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study.
    Tubaro A; Velotti F; Stoppacciaro A; Santoni A; Vicentini C; Bossola PC; Galassi P; Pettinato A; Morrone S; Napolitano T
    Cancer; 1991 Jul; 68(1):56-61. PubMed ID: 2049753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer.
    Ferlazzo G; Magno C; Lupo G; Rizzo M; Iemmo R; Semino C; Melioli G
    Am J Clin Oncol; 1995 Apr; 18(2):100-4. PubMed ID: 7900700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
    Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
    Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
    Ferlazzo G; Magno C; Iemmo R; Rizzo M; Lupo G; Semino C; Bruno S; Melioli G
    Anticancer Res; 1996; 16(2):979-80. PubMed ID: 8687163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2.
    Grasso M; Torelli F; Scannapieco G; Franzoso F; Lania C
    J Immunother; 2001; 24(2):184-7. PubMed ID: 11265776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
    Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors].
    Fujioka T; Shiraishi M; Tanji S; Sato S; Koike H; Aoki H; Suzuki K; Kumagai K; Banya Y; Kubo T
    Hinyokika Kiyo; 1988 Dec; 34(12):2115-9. PubMed ID: 3266444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
    Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
    Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
    Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
    Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
    Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
    Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
    J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.